Investors are increasingly looking for promising opportunities in a market characterized by volatility and swift shifts in momentum. As companies release their earnings reports, standout performances are capturing attention and influencing investment decisions.

Dan Ives, global head of technology research at Wedbush Securities, and CNBC's Eunice Yoon discuss China's pressure on Nvidia, opportunities for Chinese tech, UK AI investment, and crypto's AI intersection as regulation ramps up.

Partnering with the likes of Arista, RTX and Jabil, PCB leader TTM Technologies builds AI infrastructure as it looks to break out.

NEW YORK, NY / ACCESS Newswire / September 17, 2025 / Every once in a while, an industry has its thunderbolt moment. Recycling just had its.

DARMSTADT, Germany--(BUSINESS WIRE)--Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. New four-year data from two large Phase 4 studies highlight the long-term efficacy, favorable disability outcomes and durable impact of MAVENCLAD® (cladribine tablets) in people living with relapsing multiple sclerosis (RMS). These findings are to be presented at the.

RICHMOND, Va.--(BUSINESS WIRE)--NewMarket Corporation (NYSE: NEU) today announced its entry into a definitive purchase agreement to acquire Mars TopCo, LLC, the ultimate parent company of Calca Solutions, LLC (Calca). Calca is currently a portfolio company of AE Industrial Partners, LP. Based in Lake Charles, Louisiana, Calca is the leading U.S. manufacturer of UltraPure and high purity hydrazine – mission critical chemicals used in a wide range of applications. Most notably, these products are.

NEW YORK & LONDON & MUMBAI, India--(BUSINESS WIRE)---- $WNS #Acquisition--WNS updates progress on acquisition by Capgemini.

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): Data from the completed phase 3 SOLARIS trial to be presented at the 2025 Psych Congress Annual Meeting, taking place from September 17 – 21, 2025, in San Diego, California Teva will host a conference call for analysts and investors on Monday, September 22, 2025, at 11:00 am ET to discuss these data To access a live webcast of the presentation, visit Teva's Investor Relations website at https://ir.tevapharm.com/Even.

MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced it has renewed its sponsorship agreement with professional golfer Neal Shipley and signed new sponsorship agreements with Bud Cauley, Ryan Fox and Darren Clarke. These endorsements reflect Claritev's commitment to supporting athletes who exemplify resilience, determinatio.

The biggest names in tech are racing to make advertising easier, especially for small businesses and consumer goods companies.

FORT LEE, N.J.--(BUSINESS WIRE)--Luxa Biotechnology LLC (Luxa), a clinical-stage biotechnology company developing novel adult retinal pigment epithelial stem cell (RPESC) therapies for dry age-related macular degeneration (dry AMD), today announced the publication of Phase 1/2a clinical trial results in a paper titled "Safety and Tolerability of RPE Stem Cell-derived RPE Transplantation in Patients with Dry Age-related Macular Degeneration: Low Dose Clinical Outcomes" in the journal Cell Stem C.

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive initial results from the Phase 1a trial of STAR-0310, a YTE half-life extended monoclonal antibody antagonist of OX40, in healthy subjects. STAR-0310 demonstrated a best-in-class half-life of up to 68 days, consistent with administration every six months, durable cytokine inhibition, and was we.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the publication of two peer-reviewed research papers describing innovative bioproduction strategies for creating therapeutic compounds. While Enveric's lead candidate EB-003 is manufactured using established synthetic chemistry methods common to the.

IRVINE, Calif.--(BUSINESS WIRE)--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the launch of a new brand, “Hada no Aozora Clinic”, scheduled to open in Tokyo on October 1, 2025. This clinic will adopt a hybrid dermatology model that integrates insurance-covered general dermatology and private-pay aesthetic treatments, advancing SBC's multi.

CHICAGO--(BUSINESS WIRE)--Alight, Inc. (NYSE: ALIT), a leading cloud-based human capital and technology-enabled services provider, today announced the addition of Sword Health, a musculoskeletal and mental health AI care platform, to its Alight Partner Network. "The Alight Partner Network delivers a range of fully integrated solutions that differentiates the benefits experience for participants and HR programs," said Missy Van Brocklin, Vice President of Partners at Alight. "The addition of Swo.

NYSE: VZLA TSX: VZLA VANCOUVER, BC , Sept. 17, 2025 /PRNewswire/ - Vizsla Silver Corp. (TSX: VZLA) (NYSE: VZLA) (Frankfurt: 0G3) ("Vizsla" or the "Company") is pleased to announce that Mr.

STAMFORD, Conn., Sept. 17, 2025 /PRNewswire/ -- Synchrony (NYSE: SYF) plans to report its third quarter 2025 results on Wednesday, October 15, 2025.

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed sustained skin clearance and favorable safety profile in both adults and adolescents at Week 52 in Phase 3 ICONIC-LEAD study Robust findings continue to demonstrate the potential of icotrokinra to disrupt the treatment paradigm to set a new standard for treating patients with moderate-to-severe plaque psoriasis SPRING HOUSE, Pa. , Sept. 17, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ICONIC-ADVANCE 1 and 2 …

SEATTLE, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS; “Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, today announces it has appointed CORE IR, a strategic investor relations, public relations, and corporate advisory firm, to support the Company's ongoing investor relations and communications initiatives.

Projects to Power a Combined Equivalent of 1,140 Homes Annually Part of Nova Scotia's Ambitious 80% Renewable Energy by 2030 Initiative Enables Residents and Businesses to Access Solar Without Rooftop Installation Projects to Provide a Total of Approximately 14,369 MWh of Clean Energy to the Province Annually, Equivalent to Removing Approximately 10,058 Tonnes of CO2 Emissions and 3,081 Passenger Vehicles from the Road TORONTO , Sept. 17, 2025 /PRNewswire/ - PowerBank Corporation (NASDAQ: SUUN) (CBOE CA: SUNN) (FSE: 103) ("PowerBank" or the "Company"), a leader in North American energy infrastructure development and asset ownership, is pleased to share a progress …